Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-05-08
2007-05-08
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S501000, C436S518000
Reexamination Certificate
active
10106559
ABSTRACT:
The present invention provides methods and compositions for the diagnosis of hyperproliferative disease and autoimmune disease. Tumor associated antigens, nucleic acids encoding them and antibodies to the tumor associated antigens are provided for the diagnosis of hyperproliferative disease, such as, for example, ovarian cancer, breast cancer, lung cancer, colorectal cancer, and other epithelial cancers, and for the diagnosis of autoimmune disease.
REFERENCES:
patent: 5652115 (1997-07-01), Marks et al.
patent: 5872217 (1999-02-01), Kuhajda et al.
patent: 6004755 (1999-12-01), Wang
patent: 6645465 (2003-11-01), Hanash et al.
patent: 2001/0005582 (2001-06-01), Benistant et al.
patent: WO99/00671 (1999-01-01), None
patent: WO99/39210 (1999-08-01), None
patent: WO99/51772 (1999-10-01), None
patent: WO99/58978 (1999-11-01), None
patent: WO2003/064593 (2003-08-01), None
patent: WO2003/064593 (2003-08-01), None
Yanagidani et al., Journal of autoimmunity (ENGLAND) Aug. 2000, vol. 15, issue 1, p. 75-80.
Voet et al., (1990, Biochemistry, John Wiley & Sons, p. 816 only).
Joan Pontius, et al., UniGene, downloaded on Apr. 11, 2006 from NCBI website, created Oct. 9, 2002, and updated Aug. 13, 2003.
Motfort-Cabello, 2004, Homeopathy, vol. 93, pp. 88-93, abstract only.
Definition of “Malignant” the online dictionary downloaded from world wide web, m-w.com on Apr. 12, 2006.
Cao et al., 1999, Breast Cancer Research and Treatment, vol. 53, pp. 279-290.
Bast, Jr. et al., “Reactivity of a Monoclonal Antibody with Human Ovarian Carcinoma,”J. Clin. Invest. 68:1331-1337 (Nov. 1981).
Bast, Jr. et al., “A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer,”New England Journal of Medicine309:883-887 (Oct. 13, 1983).
Piver et al., “Epidemiology and Etiology of Ovarian Cancer,”Seminars in Oncology18:177-185 (Jun. 1991).
Einhorn et al., “Prospective Evaluation of Serum CA 125 Levels for Early Detection of Ovarian Cancer,”Obstetrics&Gynecology80:14-18 (Jul. 1992).
Disis et al., “Existent T-Cell and Antibody Immunity to HER-2
eu Protein in Patients with Breast Cancer,”Cancer Research54:16-20 (Jan. 1, 1994).
Berchuck et al., “The p53 tumor suppressor gene frequently is altered in gynecologic cancers,”Am. J. Obstet. Gynecol. 170:246-252 (Jan. 1994).
Boring et al., “Cancer Statistics 1994,”CA-Cancer J. Clin. 44:7-26 (Jan./Feb. 1994).
Orth et al., “Genetic instability in human ovarian cancer cell lines,”Proc. Natl. Acad. Sci USA91:9495-9499 (Sep. 1994).
Sahin et al., “Human neoplasms elicit multiple specific immune responses in the autologous host,”Proc. Natl. Acad. Sci. USA92:11810-11813 (Dec. 1995).
Flagiello et al., “Relationship between DNA methylation and gene expression of theHOXBgene cluster in small cell lung cancers,”FEBS Letters380:103-107 (1996).
Disis et al., “High-Titer HER-2
euProtein-Specific Antibody Can Be Detected in Patients With Early-Stage Breast Cancer,”J. Clin. Oncol. 15:3363-3367 (Nov. 1997).
Jager et al., “Simultaneous Humoral and Cellular Immune Response against Cancer-Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2 binding Peptide Epitopes,”J. Exp. Med. 187:265-270 (Jan. 19, 1998).
Stockert et al., “A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens,”J. Exp. Med. 187:1349-1354 (Apr. 20, 1998).
Grigola et al., “Mapping of topoisomerase II α epitopes recognized by autoantibodies in idiopathic pulmonary fibrosis,”Clin. Exp. Immunol., 114:339-346 (1998).
Krosl et al., “Cellular proliferation and transformation induced by HOXB4 and HOXB3 proteins involves cooperation with PBX1,”Oncogene16:3403-3412 (1998).
Tavassoli et al., “p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity,”Int. J. Cancer78:390-391 (1998).
Jacobs et al., “Screening for ovarian cancer: a pilot randomised controlled trial,”The Lancet353:1207-1210 (Apr. 10, 1999).
Disis et al., “Generation of Immunity to the HER-2
euOncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-based Vaccine,”Clin. Cancer Res. 5:1289-1297 (Jun. 1999).
Hengstler et al., “Contribution ofc-erbB-2and Topoisomerase IIα to Chemoresistance in Ovarian Cancer,”Cancer Res. 59:3206-3214 (Jul. 1, 1999).
Golub et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring,”Science286:531-537 (Oct. 15, 1999).
Gadducci et al., “Assessment of the Prognostic Relevance of Serum Anti-p53 Antibodies in Epithelial Ovarian Cancer,”Gynecologic Oncology72:76-81 (1999).
Schummer et al., “Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas,”Gene238:375-385 (1999).
Jarvinen et al., “Amplification and Deletion of Topoisomerase IIα Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast Cancer,”Am. J. Pathol. 156:839-847 (Mar. 2000).
Jager et al., “Monitoring CD8 cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses,”PNAS97:4760-4765 (Apr. 25, 2000).
Baldwin et al., “BRCA1Promoter Region Hypermethylation in Ovarian Carcinoma: A Population-based Study,”Cancer Research60:5329-5333 (Oct. 1, 2000).
Abendstein et al., “Clinical Significance of Serum and Ascitic p53 Autoantibodies in Epithelial Ovarian Carcinoma,”Cancer1432-1437 (2000).
Bodey et al., “Immunocytochemical Detection of the Homeobox B3, B4, and C6 Gene Products in Breast Carcinomas,”Anticancer Res. 20:3281-3286 (2000).
Disis et al., “Pre-existent immunity to the HER-2
eu oncogenic protein in patients with HER-2
eu overexpressing breast and ovarian cancer,”Breast Cancer Res. Treat. 62:245-252 (2000).
Fishman et al., “Is Transvaginal Ultrasound Effective for Screening Asymptomatic Women for the Detection of Early-Stage Epithelial Ovarian Carcinoma?”Gynecol. Oncol. 77:347-349 (2000).
Vogl et al., “Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass,”British J. Cancer83:1338-1343 (2000).
Wamakulasuriya et al., “Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients,”J. Pathol. 192:52-57 (2000).
Welsh et al., “Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer,”PNAS98:1176-1181 (Jan. 30, 2001).
Thorsteinsdottir et al., “Defining Roles forHOXandMEISIGenes in Induction of Acute Myeloid Leukemia,”Mol. Cell. Biol. 21:224-234 (Jan. 2001).
Stone et al., “Proceeding of American Association for Cancer Research 2001,” abstract No. 7583 (posted online on Feb. 27, 2001; mailed out in printed form on Mar. 10, 2001).
Ovarian Cancer—Internet Website: http://health.yahoo.com/health/Diseases—and—Conditions/Disease—Feed—Data/ovarian—cancer/ (printed Mar. 13, 2001).
Stages of Ovarian Cancer—Internet Website: http://health.yahoo.com/health/women/dealing5d.html (printed Mar. 13, 2001).
Imai et al., “Autoantibody to DNA Topoisomerase II in Primary Liver Cancer,”Clinical Cancer Research, (Apr. 1995), vol. 1, pp. 417-424.
Zanaboni et al. “Tumor Antigen CA 125 as a Marker of Ovarian Epithelial Carcinoma,”Gynecol. Oncol. 28:61-67 (1987).
Young et al., “ERBB2and Chromosome 17 Centromere Studies of Ovarian Cancer by Fluorescence In Situ Hybridization,”Genes, Chromosomes&Cancer16:130-137 (1996).
Hung and Satyaswaro
Nelson Brad H.
Stone Bradley C.
Benaroya Research Institute at Virginia Mason
Yu Misook
LandOfFree
Tumor associated antigens and methods of using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor associated antigens and methods of using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor associated antigens and methods of using the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3763111